Blood Test for Alzheimer's Gets a Major Accuracy Upgrade with p-tau217
A landmark meta-analysis of 29,625 people finds plasma p-tau217 detects Alzheimer's pathology with ~88% sensitivity and specificity.
20 articoli
A landmark meta-analysis of 29,625 people finds plasma p-tau217 detects Alzheimer's pathology with ~88% sensitivity and specificity.
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
A fully automated plasma p-tau217 test accurately identifies Alzheimer's pathology across 1,767 patients in primary and secondary care settings.
Plasma eMTBR-tau243 outperforms current tau biomarkers in identifying tau tangle pathology and predicting cognitive decline in Alzheimer's disease.
New biomarker could identify dementia risk decades before symptoms appear, enabling earlier intervention strategies.
New study shows plasma pTau217 test reliably identifies Alzheimer's pathology in the brain, even when other dementia types are present.
Researchers developed plasma p-tau217 clocks that predict when cognitively healthy people will develop Alzheimer's symptoms within 3-4 years.
New p-tau217 blood test forecasts Alzheimer's symptoms within 3-4 years, potentially revolutionizing early intervention strategies.
Brain-derived pTau217 blood test shows superior accuracy for detecting Alzheimer's pathology compared to existing tests.
Uno studio della Mayo Clinic rivela che il rapporto plasmatico Lumipulse p-tau217/Aβ42 presenta un'accuratezza variabile nel rilevare la patologia amiloide dell'Alzheimer.
New blood test using 7,000 proteins creates biological aging clock and disease trajectory that better predicts Alzheimer's risk than current methods.
A 7-protein plasma panel predicts Alzheimer's with AUC >0.88, validated across 10,000+ samples from multiple cohorts and platforms.
Comprehensive review reveals TPE could shift from reactive treatment to preventative therapy for cardiovascular, metabolic, and neurological aging.
New evidence-based guideline defines performance thresholds for blood tests that can replace costly PET and CSF testing in specialized AD care.
Un accordo di licenza per 9 anticorpi Tau specializzati potrebbe aiutare a distinguere l'Alzheimer da altre malattie cerebrali anni prima che compaiano i sintomi.
Large study reveals women accumulate toxic tau proteins faster than men, potentially explaining higher Alzheimer's risk.
Una nuova ricerca mostra che la patologia tau compromette il trasporto intracellulare neuronale prima ancora che si formino i grovigli — e un inibitore della chinasi è in grado di invertirlo.
French study reveals antibody trajectory patterns that could guide treatment decisions in thrombotic thrombocytopenic purpura.
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
Scientists discover tau isn't just an Alzheimer's villain — it's essential for encoding lasting memories in healthy neurons.